Physician
Oncology
Dr. Jared A. Gollob, MD
Jared A. Gollob, MD works in the field of Oncology. Doctor Jared A. Gollob, MD has written publications. He has 17 publications published with PubMed. The lastest publication is: 'Safety profile of RNAi nanomedicines.'
Publications
- Safety profile of RNAi nanomedicines.
- Defining the Critical Hurdles in Cancer Immunotherapy.
- RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
- Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells.
- Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
- Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
- Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
- Historic evidence and future directions in clinical trial therapy of solid tumors.
- Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
- Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma.
- Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
- Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.
- Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
- A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
- Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer.
- IL-12 induces monocyte IL-18 binding protein expression via IFN-gamma.
Schools
Columbia University College of Physicians And Surgeons
Massachusetts General Hospital
Dana Farber Cancer Institute
Harvard Med School
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Helpful Reviews
Similar Doctors
|
Dr. Anna Berkenblit, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Erin R. Derose, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth G. Trehu, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Cynthia A. Sirard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William R. Sellers, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Anthony L. Boral, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa B. Weissmann, MD
This Doctor is OpenDoctor Recommended.
|